Connect with us

Business

Cannabis Does a Better Job for Cancer Pain Than Opioids? – New Medical Study Changes Cancer Treatment Thinking

Published

on

Medical cannabis is safe and effective for treating lingering cancer pain in patients

Study Finds That Cannabis Is Safe For Treating Cancer Pain – Cancer Patients No Longer Need Opioids

As if being diagnosed with the Big C wasn’t bad enough, cancer patients often have to deal with a multitude of other debilitating conditions, with the worst being cancer-related pain.

While a cancer diagnosis doesn’t automatically mean you’ll be in pain, some 55% of cancer patients and 40% of survivors still suffer from chronic pain. Almost half of patients have to use opioids to manage the severe pain caused by the cancer itself which in most cases prevents patients as well as survivors from living a normal life. There are many factors that contribute to how much pain one feels; some days may be filled with pain while others are more tolerable, but no matter what, pain shouldn’t be accepted as part of cancer. There are treatments that are safe and effective available.

Unfortunately, opioid medications have become the standard treatment for severe pain, cancer or not. These ultra-strong chemical drugs may be effective at numbing pain, but at what cost? The opioid epidemic in America has taken millions of lives because it’s far too easy to overdose on it. Yet medical professionals continue to prescribe opioids to cancer patients and other terminally ill because it’s what helps them manage pain.

Opioids are extremely addictive, and even the slightest overdose can cause death.

So what are cancer patients struggling with pain left to do?

Cannabis is a Safe Alternative to Opioids

Medical marijuana has been making waves for its powerful ability to treat pain safely and naturally. This is critical for cancer patients.

brand-new assessment focusing on the therapeutic benefits of marijuana for pain caused by cancer confirms this. The study, which was published in the medical journal, Frontiers in Pain Research, was conducted by researchers in Israel. “Traditionally, cancer-related pain is mainly treated by opioid analgesics, but most oncologists perceive opioid treatment as hazardous, so alternative therapies are required,” says David Meiri, the study’s author, and an assistant professor at the Technion Israel Institute of Technology.

“Our study is the first to assess the possible benefits of medical cannabis for cancer-related pain in oncology patients; gathering information from the start of treatment and with repeated follow-ups for an extended period of time, to get a thorough analysis of its effectiveness,” he said.

For the assessment, they spoke with cancer patients who were seeking other choices available to treat their pain as well as other cancer symptom relief. They then worked with oncologists who issued a license for medical cannabis for their cancer patients, and interested patients who wanted to join the study were asked for their feedback.

“We encountered numerous cancer patients who asked us whether medical cannabis treatment can benefit their health,” explains Gil Bar-Sela, the study’s co-author, who is also an associate professor at the Ha’Emek Medical Center Afula.

The authors particularly wanted to get more information on cannabis for cancer-related pain. “Our review of existing research revealed that actually not much was known regarding its effectiveness, particularly for the treatment of cancer-related pain, and of what was known, most findings were inconclusive,” he adds.

“Patients completed anonymous questionnaires before starting treatment, and again at several time points during the following six months. We gathered data on a number of factors, including pain measures, analgesics consumption, cancer symptom burden, sexual problems, and side effects,” Bar-Sela adds.

After reviewing the data, the researchers found that a great deal of outcome measures revealed improvements. Cancer symptoms as well as pain scores were reduced though it was more significant that the patients were able to stop their intake of opioids or other painkillers. Additionally, they reported that almost half the participants were successfully able to wean off all painkillers just 6 months after treatment with medical marijuana.

“Medical cannabis has been suggested as a possible remedy for appetite loss, however, most patients in this study still lost weight. As a substantial portion were diagnosed with progressive cancer, a weight decline is expected with disease progression,” Meiri said.

Other Studies Reflect Similar Findings

In a 2021 clinical trial conducted by researchers at Minnesota’s Cancer Research Center together with the Minnesota Department of Health involved analyzing patients with stage IV cancer and their consumption of opioids and license cannabis products.

Thirty participants in the study were tasked to consume plant-derived extracts during the trial, starting at 2.5-5mg of THC/CBD, increasing to 30-40mg of THC and CBD each day for the course of the study which lasted two to four weeks. “Medical cannabis use led to improvements in achieving personalized pain goals and lower overall opioid requirements. No serious adverse events with cannabis were reported, and most patients who used cannabis reported that benefits outweighed negative effects.”

“Our results support prior studies suggesting cannabis may improve pain and minimize opioid utilization in both cancer and non-cancer settings… Incorporating cannabis into routine cancer care may improve pain control and minimize opioid requirements,” the authors concluded.

Meanwhile, a 2018 assessment from the European Journal of Internal Medicine, conducted by Tikun Olam researchers, looked at how effective cannabis was for cancer patients. They found that cannabis was efficient in decreasing cancer patients’ intake of opioids within 6 months from the time they started consuming it.

 Lihi Bar-lev Schleider, the study’s lead researcher, disclosed to the Rolling Stone that, “Cannabis is a very good alternative to reduce opioid consumption, to increase quality of life, and to reduce pain, nausea and vomiting.”

Conclusion

There is solid data out there about the efficacy of cannabis for treating cancer symptoms, including pain – which in itself is already very difficult to treat. If you or a loved one is taking opioid medications for cancer, speak to your oncologist about weaning off the drugs and switching to cannabis instead for a safer experience and improved quality of life.

Source: https://cannabis.net/blog/medical/cannabis-does-a-better-job-for-cancer-pain-than-opioids-new-medical-study-changes-cancer-treatm

Business

New Mexico cannabis operator fined, loses license for alleged BioTrack fraud

Published

on

New Mexico regulators fined a cannabis operator nearly $300,000 and revoked its license after the company allegedly created fake reports in the state’s traceability software.

The New Mexico Cannabis Control Division (CCD) accused marijuana manufacturer and retailer Golden Roots of 11 violations, according to Albuquerque Business First.

Golden Roots operates the The Cannabis Revolution Dispensary.

The majority of the violations are related to the Albuquerque company’s improper use of BioTrack, which has been New Mexico’s track-and-trace vendor since 2015.

The CCD alleges Golden Roots reported marijuana production only two months after it had received its vertically integrated license, according to Albuquerque Business First.

Because cannabis takes longer than two months to be cultivated, the CCD was suspicious of the report.

After inspecting the company’s premises, the CCD alleged Golden Roots reported cultivation, transportation and sales in BioTrack but wasn’t able to provide officers who inspected the site evidence that the operator was cultivating cannabis.

In April, the CCD revoked Golden Roots’ license and issued a $10,000 fine, according to the news outlet.

The company requested a hearing, which the regulator scheduled for Sept. 1.

At the hearing, the CCD testified that the company’s dried-cannabis weights in BioTrack were suspicious because they didn’t seem to accurately reflect how much weight marijuana loses as it dries.

Company employees also poorly accounted for why they were making adjustments in the system of up to 24 pounds of cannabis, making comments such as “bad” or “mistake” in the software, Albuquerque Business First reported.

Golden Roots was fined $298,972.05 – the amount regulators allege the company made selling products that weren’t properly accounted for in BioTrack.

The CCD has been cracking down on cannabis operators accused of selling products procured from out-of-state or not grown legally:

Golden Roots was the first alleged rulebreaker in New Mexico to be asked to pay a large fine.

Source: https://mjbizdaily.com/new-mexico-cannabis-operator-fined-loses-license-for-alleged-biotrack-fraud/

Continue Reading

Business

Marijuana companies suing US attorney general in federal prohibition challenge

Published

on

Four marijuana companies, including a multistate operator, have filed a lawsuit against U.S. Attorney General Merrick Garland in which they allege the federal MJ prohibition under the Controlled Substances Act is no longer constitutional.

According to the complaint, filed Thursday in U.S. District Court in Massachusetts, retailer Canna Provisions, Treevit delivery service CEO Gyasi Sellers, cultivator Wiseacre Farm and MSO Verano Holdings Corp. are all harmed by “the federal government’s unconstitutional ban on cultivating, manufacturing, distributing, or possessing intrastate marijuana.”

Verano is headquartered in Chicago but has operations in Massachusetts; the other three operators are based in Massachusetts.

The lawsuit seeks a ruling that the “Controlled Substances Act is unconstitutional as applied to the intrastate cultivation, manufacture, possession, and distribution of marijuana pursuant to state law.”

The companies want the case to go before the U.S. Supreme Court.

They hired prominent law firm Boies Schiller Flexner to represent them.

The New York-based firm’s principal is David Boies, whose former clients include Microsoft, former presidential candidate Al Gore and Elizabeth Holmes’ disgraced startup Theranos.

Similar challenges to the federal Controlled Substances Act (CSA) have failed.

One such challenge led to a landmark Supreme Court decision in 2005.

In Gonzalez vs. Raich, the highest court in the United States ruled in a 6-3 decision that the commerce clause of the U.S. Constitution gave Congress the power to outlaw marijuana federally, even though state laws allow the cultivation and sale of cannabis.

In the 18 years since that ruling, 23 states and the District of Columbia have legalized adult-use marijuana and the federal government has allowed a multibillion-dollar cannabis industry to thrive.

Since both Congress and the U.S. Department of Justice, currently headed by Garland, have declined to intervene in state-licensed marijuana markets, the key facts that led to the Supreme Court’s 2005 ruling “no longer apply,” Boies said in a statement Thursday.

“The Supreme Court has since made clear that the federal government lacks the authority to regulate purely intrastate commerce,” Boies said.

“Moreover, the facts on which those precedents are based are no longer true.”

Verano President Darren Weiss said in a statement the company is “prepared to bring this case all the way to the Supreme Court in order to align federal law with how Congress has acted for years.”

While the Biden administration’s push to reschedule marijuana would help solve marijuana operators’ federal tax woes, neither rescheduling nor modest Congressional reforms such as the SAFER Banking Act “solve the fundamental issue,” Weiss added.

“The application of the CSA to lawful state-run cannabis business is an unconstitutional overreach on state sovereignty that has led to decades of harm, failed businesses, lost jobs, and unsafe working conditions.”

Source: https://mjbizdaily.com/marijuana-companies-suing-us-attorney-general-to-overturn-federal-prohibition/

Continue Reading

Business

Alabama to make another attempt Dec. 1 to award medical cannabis licenses

Published

on

Alabama regulators are targeting Dec. 1 to award the first batch of medical cannabis business licenses after the agency’s first two attempts were scrapped because of scoring errors and litigation.

The first licenses will be awarded to individual cultivators, delivery providers, processors, dispensaries and state testing labs, according to the Alabama Medical Cannabis Commission (AMCC).

Then, on Dec. 12, the AMCC will award licenses for vertically integrated operations, a designation set primarily for multistate operators.

Licenses are expected to be handed out 28 days after they have been awarded, so MMJ production could begin in early January, according to the Alabama Daily News.

That means MMJ products could be available for patients around early March, an AMCC spokesperson told the media outlet.

Regulators initially awarded 21 business licenses in June, only to void them after applicants alleged inconsistencies with how the applications were scored.

Then, in August, the state awarded 24 different licenses – 19 went to June recipients – only to reverse themselves again and scratch those licenses after spurned applicants filed lawsuits.

A state judge dismissed a lawsuit filed by Chicago-based MSO Verano Holdings Corp., but another lawsuit is pending.

Source: https://mjbizdaily.com/alabama-plans-to-award-medical-cannabis-licenses-dec-1/

Continue Reading

Trending

Copyright © 2022 420 Reports Marijuana News & Information Website | Reefer News | Cannabis News